Noteworthy, FLT3i quizartinib and JAK1/2i ruxolitinib enhanced the effect of the combinations of Polθi + ALDHi and Polθi + ADH5i in AML and MPN patient cells. This evidence concerns the gene POLI and myeloproliferative disorder.